Mastitis in cows is one of the most prevalent illnesses affecting the dairy food industry. Bovine mastitis is an inflammation of the mammary gland in cattle due to injury or illness that results in abnormal and reduced milk output.
The global bovine mastitis market generated $0.54 billion in 2021, and is estimated to reach $1.01 billion by 2031, witnessing a CAGR of 6.3% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/17988
- CAGR: 6.3%
- Current Market Size: USD 1.01 Billion
- Forecast Growing Region: APAC
- Largest Market: North America
- Projection Time: 2021 – 2031
- Base Year: 2021
Covid-19 Scenario:
- The COVID-19 outbreak had a negative impact on the growth of the bovine mastitis market, owing to the implementation of lockdown in many countries which affected the supply chain for farms and dairy industry.
- The entire healthcare industry focused on life saving and COVID-19 related products which restricted the treatment for bovine mastitis.
- However, the healthcare sector has been restructured to provide safer healthcare facilities. Hence, the market is likely to grow in the post pandemic period.
Based on product, the antibiotics segment held the largest share in 2021, contributing to nearly two-thirds of the global bovine mastitis market, and is likely to maintain its leadership status during the forecast period. However, the others segment is expected to manifest the highest CAGR of 7.0% from 2022 to 2031.
Speak to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/17988
Based on route of administration, the systemic segment had the largest share in 2021, accounting for nearly three-quarters of the global bovine mastitis market, and will dominate until 2031. However, the inframammary segment is estimated to witness the fastest CAGR of the 6.9% during the forecast period. According to the app, the in situ treatment segment had the largest share in 2021, accounting for nearly three-quarters of the global bovine mastitis market, and will dominate through 2031. The same segment is estimated to witness the fastest CAGR of 6.4% during the forecast period.
Based on region, the Asia-Pacific market was the largest in 2021, accounting for nearly half of the global bovine mastitis market, and is likely to maintain its lead over the forecast period. However, the LAMEA region is projected to experience the highest CAGR of 6.6% between 2022 and 2031. The other regions analyzed in the study include Europe and North America.
Leading players of the global bovine mastitis market analyzed in the research include Armenta Ltd.,
Boehringer Ingelheim Gmbh,
Ecolab Inc.,
Forte Healthcare Ltd.,
Huvepharma nv,
Merck KGaA, Mileutis Ltd,
Neogen Corporation,
Thermo Fisher Scientific Inc, and Zoetis Inc.